Sucampo Looks To Add Heft With Vtesse Acquisition

03 Apr 2017

In search of a new direction since shelving cobiprostone last summer, Sucampo acquires Cydan-backed startup and Niemann-Pick disease candidate VTS-270, now in a pivotal Phase IIb/III study.

Troubled Sucampo Pharmaceuticals Inc. is placing a $200m wager on the potential of bringing the first drug therapy for the rare disorder Niemann-Pick Disease Type C1 (NPC-1) to market, announcing a cash-and-stock buyout of privately held Vtesse Inc. and its pivotal-stage VTS-270 on April 3.

Sucampo has been struggling since it decided to shelve its lead pipeline candidate, cobiprostone, last July following clinical disappointments in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

24 Jul 2025

• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

23 Jul 2025

• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.